Health6 months ago
Oral PCSK9 Inhibitor Poised to Transform Cholesterol Management
A new oral medication, enlicitide decanoate, developed by Merck & Co., is set to revolutionize cholesterol management by providing significant reductions in low-density lipoprotein cholesterol (LDL-C)...
